|Bid||5.41 x 3200|
|Ask||5.52 x 1400|
|Day's Range||5.36 - 5.70|
|52 Week Range||1.76 - 7.07|
|Beta (5Y Monthly)||2.65|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
ImmunoGen Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
ImmunoGen Announces Webcast of Presentation and Q&A at the 38th Annual J.P. Morgan Healthcare Conference
NEW YORK, NY / ACCESSWIRE / August 2, 2019 / ImmunoGen, Inc. (NASDAQ: IMGN ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August 2, 2019, 2018 at 8:00 AM ...
ImmunoGen, Inc., (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the completion of an in-depth operational review designed to extend the Company’s cash runway and deliver on its commitment to develop next-generation ADCs to bring more good days to patients and generate increased value for shareholders. Based on the outcomes of this review, the Company will prioritize continued development of mirvetuximab and a select portfolio of three earlier-stage product candidates targeting solid tumors and hematological malignancies. The Company will end the current quarter with approximately $240 million on its balance sheet and expects this cash, together with expense reductions resulting from the operational changes announced today and anticipated cash receipts from partners, will fund operations through the release of top-line results from the upcoming mirvetuximab Phase 3 study in platinum-resistant ovarian cancer, which are expected in the first half of 2022.
NEW YORK, NY / ACCESSWIRE / June 3, 2019 / Pomerantz LLP is investigating claims on behalf of investors of ImmunoGen, Inc. ("ImmunoGen" or the "Company") (IMGN). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. The investigation concerns whether ImmunoGen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.